Article
Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Internal medicine (Tokyo, Japan) - 1 May 2018
Hirayama Takeshi, Ikegami Tadashi, Honda Akira, Miyazaki Teruo, Yara Sho-Ichiro, Kohjima Motoyuki, Nakamuta Makoto, Matsuzaki Yasushi
Abstract excerpt
Objective Since the majority of direct-acting antivirals (DAAs) that are used in the treatment of hepatitis C virus (HCV) infection are mainly metabolized by CYP3A4, it is hypothesized that inter-individual differences in CYP3A4 activity may be associated with the bioavailability of these agents. Methods The level of serum 4β-hydroxycholesterol (4βHC), a surrogate marker of CYP3A4 activity, was determined by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.